Abstract : Despite the success of targeted therapies in managing immune-mediated inflamma-tory diseases (IMIDs) such as RA, IBDs, MS and psoriasis, unmet needs for such approach in SLE are widely recognized. In the past 2 years, exciting insights supporting previous lines of evidence on the role of the IL-23/IL-17 axis in SLE have emerged. This is of particular importance as IL-17 blockers have now moved successfully into the clinical space, as illustrated in psoriasis and ankylosing spondylitis. However, recent fundamental studies also highlighted unexpected aspects of IL-17/Th17 biology whose comprehension may prevent disappointing results of IL-17 targeting such as those obtained in Crohn's disease. Therefore, establishing a current picture of the IL-17 pre-clinical situation in SLE is timely in order to plan future proof-of-concept studies in human.
https://www.hal.inserm.fr/inserm-02164493
Contributor : Ana Paula Dutra Azevedo
<>
Submitted on : Tuesday, June 25, 2019 - 10:23:39 AM
Last modification on : Saturday, June 29, 2019 - 1:31:49 AM
File
Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed
until : jamais
